Boivin-Champeaux Clémence, Velez de Mendizabal Nieves, Jones Aksana, Balsitis Scott, Schmidt Stephan, Feigelman Justin S, Azeredo Francine Johansson
Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Clinical Pharmacology and Pharmacometrics, Gilead Sciences, Foster City, California, USA.
CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):420-434. doi: 10.1002/psp4.13298. Epub 2024 Dec 27.
Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states. This tutorial elucidates essential considerations for establishing a disease modeling platform to facilitate informed decision-making in hepatitis B treatment strategies. We review several published models of varying complexity and describe the context that motivated each model's structure and assumptions. Several of the models are made available in an interactive RShiny app to demonstrate the influence of model choice and sensitivity to the choice of parameter values.
慢性乙型肝炎带来了重大的健康和社会经济负担。尽管有可用的治疗方法,但肝细胞癌的风险仍然很高。要实现最佳治疗方案,就需要深入理解病毒与其宿主在不同疾病状态下的动态关系。本教程阐明了建立疾病建模平台的重要考虑因素,以促进在乙型肝炎治疗策略中做出明智的决策。我们回顾了几个已发表的、复杂度各异的模型,并描述了促使每个模型的结构和假设形成的背景。其中几个模型可在一个交互式RShiny应用程序中使用,以展示模型选择的影响以及对参数值选择的敏感性。